Compare SCLX & BTCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCLX | BTCS |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 148.0M |
| IPO Year | N/A | N/A |
| Metric | SCLX | BTCS |
|---|---|---|
| Price | $17.70 | $3.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 119.6K | ★ 1.4M |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | ★ 1.48% |
| EPS Growth | N/A | ★ 644.42 |
| EPS | N/A | ★ 1.76 |
| Revenue | ★ $40,360,000.00 | $11,724,983.00 |
| Revenue This Year | N/A | $248.05 |
| Revenue Next Year | $749.70 | $41.01 |
| P/E Ratio | ★ N/A | $1.92 |
| Revenue Growth | N/A | ★ 464.28 |
| 52 Week Low | $3.60 | $1.25 |
| 52 Week High | $34.27 | $8.49 |
| Indicator | SCLX | BTCS |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 53.54 |
| Support Level | $18.34 | $3.28 |
| Resistance Level | $20.62 | $3.45 |
| Average True Range (ATR) | 2.14 | 0.22 |
| MACD | -0.28 | 0.10 |
| Stochastic Oscillator | 1.86 | 89.84 |
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.